The results of two phase 3 trials investigating Survodutide, a weight loss drug from Boehringer Ingelheim, suggest that the ...

Chrome, Edge, and Firefox are often set to be too intrusive. With these five changes, you can improve privacy, security and ...

Scaling AI infrastructure is becoming a synchronization challenge, not just a capacity challenge. Early data center buildouts ...

Data centers go offline. Regions have issues. Services that everything depends on suddenly stop responding. Sometimes it’s a ...

Next-generation software platform helps operators manage High-Accuracy Time Transfer (HA-TT) connections, provides GNSS ...

NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced a new Global Data Synchronization Network (GDSN) capability within NIQ Product Intelligence, extending the ability to ...

Boehringer Ingelheim spent the weekend pointing to survodutide's “targeted” weight loss, but the latest data couldn’t shake off concerns about the obesity drug’s tolerability. The deep dive into ...

Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...

NetEase Games' party game Eggy Party today launched on Windows, bringing the full experience to PC players with ...